CN102631518A - New medicament for treating leukemia - Google Patents
New medicament for treating leukemia Download PDFInfo
- Publication number
- CN102631518A CN102631518A CN2012100944447A CN201210094444A CN102631518A CN 102631518 A CN102631518 A CN 102631518A CN 2012100944447 A CN2012100944447 A CN 2012100944447A CN 201210094444 A CN201210094444 A CN 201210094444A CN 102631518 A CN102631518 A CN 102631518A
- Authority
- CN
- China
- Prior art keywords
- radix
- parts
- herba
- rhizoma
- leukemia
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 title claims abstract description 36
- 208000032839 leukemia Diseases 0.000 title claims abstract description 34
- 238000011282 treatment Methods 0.000 claims abstract description 33
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims abstract description 19
- 235000003140 Panax quinquefolius Nutrition 0.000 claims abstract description 19
- 235000008434 ginseng Nutrition 0.000 claims abstract description 19
- 229940079593 drug Drugs 0.000 claims abstract description 11
- 241000208340 Araliaceae Species 0.000 claims description 18
- 239000002547 new drug Substances 0.000 claims description 15
- 241001675558 Galium spurium Species 0.000 claims description 9
- 241000222336 Ganoderma Species 0.000 claims description 9
- 241000628997 Flos Species 0.000 claims description 8
- QQILFGKZUJYXGS-UHFFFAOYSA-N Indigo dye Chemical compound C1=CC=C2C(=O)C(C3=C(C4=CC=CC=C4N3)O)=NC2=C1 QQILFGKZUJYXGS-UHFFFAOYSA-N 0.000 claims description 8
- 239000000796 flavoring agent Substances 0.000 claims description 8
- 235000019634 flavors Nutrition 0.000 claims description 8
- 229910052957 realgar Inorganic materials 0.000 claims description 8
- 241001619461 Poria <basidiomycete fungus> Species 0.000 claims description 7
- 239000010231 banlangen Substances 0.000 claims description 7
- 229940126678 chinese medicines Drugs 0.000 claims description 6
- 239000008361 herbal raw material Substances 0.000 claims description 4
- 238000000034 method Methods 0.000 claims description 4
- 210000004369 blood Anatomy 0.000 abstract description 12
- 239000008280 blood Substances 0.000 abstract description 12
- 230000000694 effects Effects 0.000 abstract description 11
- 206010028980 Neoplasm Diseases 0.000 abstract description 10
- 201000011510 cancer Diseases 0.000 abstract description 10
- 230000001093 anti-cancer Effects 0.000 abstract description 5
- 210000003734 kidney Anatomy 0.000 abstract description 5
- 102000009027 Albumins Human genes 0.000 abstract description 3
- 108010088751 Albumins Proteins 0.000 abstract description 3
- 229930012538 Paclitaxel Natural products 0.000 abstract description 3
- 230000009471 action Effects 0.000 abstract description 3
- 238000011161 development Methods 0.000 abstract description 3
- 229960001592 paclitaxel Drugs 0.000 abstract description 3
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 abstract description 3
- 241000700605 Viruses Species 0.000 abstract description 2
- 230000004087 circulation Effects 0.000 abstract description 2
- 230000013872 defecation Effects 0.000 abstract description 2
- 230000007102 metabolic function Effects 0.000 abstract description 2
- 230000011278 mitosis Effects 0.000 abstract description 2
- 231100000419 toxicity Toxicity 0.000 abstract description 2
- 230000001988 toxicity Effects 0.000 abstract description 2
- 241000510667 Conioselinum Species 0.000 abstract 2
- 240000005702 Galium aparine Species 0.000 abstract 2
- 235000014820 Galium aparine Nutrition 0.000 abstract 2
- 241000334154 Isatis tinctoria Species 0.000 abstract 2
- 240000001341 Reynoutria japonica Species 0.000 abstract 2
- 235000018167 Reynoutria japonica Nutrition 0.000 abstract 2
- 241001149649 Taxus wallichiana var. chinensis Species 0.000 abstract 2
- 241000270666 Testudines Species 0.000 abstract 2
- 244000131316 Panax pseudoginseng Species 0.000 abstract 1
- 230000003213 activating effect Effects 0.000 abstract 1
- 230000035755 proliferation Effects 0.000 abstract 1
- 239000002994 raw material Substances 0.000 abstract 1
- 230000001502 supplementing effect Effects 0.000 abstract 1
- 210000002700 urine Anatomy 0.000 abstract 1
- 235000013339 cereals Nutrition 0.000 description 20
- 210000001185 bone marrow Anatomy 0.000 description 15
- 201000010099 disease Diseases 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 6
- 210000000349 chromosome Anatomy 0.000 description 6
- 238000003745 diagnosis Methods 0.000 description 6
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 5
- 239000002775 capsule Substances 0.000 description 5
- 238000002512 chemotherapy Methods 0.000 description 5
- 210000003714 granulocyte Anatomy 0.000 description 5
- 210000000265 leukocyte Anatomy 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 4
- 208000032721 Philadelphia Chromosome Diseases 0.000 description 4
- 230000017531 blood circulation Effects 0.000 description 4
- 238000007796 conventional method Methods 0.000 description 4
- 230000002559 cytogenic effect Effects 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 210000001167 myeloblast Anatomy 0.000 description 4
- 230000001737 promoting effect Effects 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 206010000830 Acute leukaemia Diseases 0.000 description 3
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 3
- 206010018276 Gingival bleeding Diseases 0.000 description 3
- 208000024283 Gingival haemorrhages Diseases 0.000 description 3
- 102000001554 Hemoglobins Human genes 0.000 description 3
- 108010054147 Hemoglobins Proteins 0.000 description 3
- 201000003793 Myelodysplastic syndrome Diseases 0.000 description 3
- 208000002173 dizziness Diseases 0.000 description 3
- 210000003743 erythrocyte Anatomy 0.000 description 3
- 241000411851 herbal medicine Species 0.000 description 3
- 235000012054 meals Nutrition 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 238000010298 pulverizing process Methods 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 244000144730 Amygdalus persica Species 0.000 description 2
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 2
- 206010011224 Cough Diseases 0.000 description 2
- 208000032843 Hemorrhage Diseases 0.000 description 2
- 206010020880 Hypertrophy Diseases 0.000 description 2
- 206010027336 Menstruation delayed Diseases 0.000 description 2
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 2
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 2
- 240000007594 Oryza sativa Species 0.000 description 2
- 235000007164 Oryza sativa Nutrition 0.000 description 2
- 208000007541 Preleukemia Diseases 0.000 description 2
- 235000006040 Prunus persica var persica Nutrition 0.000 description 2
- 238000010322 bone marrow transplantation Methods 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- VPWFPZBFBFHIIL-UHFFFAOYSA-L disodium 4-[(4-methyl-2-sulfophenyl)diazenyl]-3-oxidonaphthalene-2-carboxylate Chemical compound [Na+].[Na+].[O-]S(=O)(=O)C1=CC(C)=CC=C1N=NC1=C(O)C(C([O-])=O)=CC2=CC=CC=C12 VPWFPZBFBFHIIL-UHFFFAOYSA-L 0.000 description 2
- 230000003760 hair shine Effects 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 230000011132 hemopoiesis Effects 0.000 description 2
- 230000002607 hemopoietic effect Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 210000001501 megacaryocyte Anatomy 0.000 description 2
- 210000001778 pluripotent stem cell Anatomy 0.000 description 2
- 231100000614 poison Toxicity 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 235000009566 rice Nutrition 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 239000003440 toxic substance Substances 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 206010004173 Basophilia Diseases 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- 208000017897 Carcinoma of esophagus Diseases 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- 101100117236 Drosophila melanogaster speck gene Proteins 0.000 description 1
- 206010014080 Ecchymosis Diseases 0.000 description 1
- 241001248531 Euchloe <genus> Species 0.000 description 1
- 239000009636 Huang Qi Substances 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- 206010062489 Leukaemia recurrent Diseases 0.000 description 1
- 206010024328 Leukaemoid reaction Diseases 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 208000028018 Lymphocytic leukaemia Diseases 0.000 description 1
- 206010028372 Muscular weakness Diseases 0.000 description 1
- 244000061176 Nicotiana tabacum Species 0.000 description 1
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 241000219000 Populus Species 0.000 description 1
- 206010037549 Purpura Diseases 0.000 description 1
- 241001672981 Purpura Species 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 206010041660 Splenomegaly Diseases 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 229930186949 TCA Natural products 0.000 description 1
- 229940123445 Tricyclic antidepressant Drugs 0.000 description 1
- 108700025716 Tumor Suppressor Genes Proteins 0.000 description 1
- 102000044209 Tumor Suppressor Genes Human genes 0.000 description 1
- 206010048245 Yellow skin Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 208000017733 acquired polycythemia vera Diseases 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 238000004820 blood count Methods 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 238000009583 bone marrow aspiration Methods 0.000 description 1
- 229960002092 busulfan Drugs 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000009104 chemotherapy regimen Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 239000007891 compressed tablet Substances 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 208000001780 epistaxis Diseases 0.000 description 1
- 201000005619 esophageal carcinoma Diseases 0.000 description 1
- 239000003172 expectorant agent Substances 0.000 description 1
- 230000003419 expectorant effect Effects 0.000 description 1
- 206010016766 flatulence Diseases 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 208000014951 hematologic disease Diseases 0.000 description 1
- 206010019847 hepatosplenomegaly Diseases 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000000366 juvenile effect Effects 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 208000030208 low-grade fever Diseases 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 208000003747 lymphoid leukemia Diseases 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 210000001237 metamyelocyte Anatomy 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000036473 myasthenia Effects 0.000 description 1
- 210000003887 myelocyte Anatomy 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 230000003448 neutrophilic effect Effects 0.000 description 1
- 210000003924 normoblast Anatomy 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 238000011369 optimal treatment Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 208000037244 polycythemia vera Diseases 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 230000010349 pulsation Effects 0.000 description 1
- 230000001047 pyretic effect Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 206010043554 thrombocytopenia Diseases 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention provides a new medicament for treating leukemia, which is prepared from 39 raw material drugs, such as taxus chinensis (tree bark), tender catchweed bedstraw herb, prismatomeria tetrandra, isatis indigotica fort, tuber fleeceflower stem, Yunnan fringed iris herb, fructus corni, hemlock parsley, turtle shell and the like, wherein the taxus chinensis (tree bark) contains 'taxol' which is the top anti-cancer medicament in the world, can be combined with trace of albumin, so that the albumin is accelerated to be aggregated, mitosis of cancer cells can be inhibited, and proliferation of the cancer cells can be effectively stopped. The medicament also comprises the tender catchweed bedstraw herb, suncured ginseng, prismatomeria tetrandra, isatis indigotica fort, tuber fleeceflower stem, Yunnan fringed iris herb, fructus corni, hemlock parsley and turtle shell, so that growth and development of the cancer cells can be controlled, the cancer resistance of a human body can be reinforced, the circulation and metabolic function of the human body can be improved, virus accumulated in the human body is removed outside the body through urine and defecation to achieve the function of preventing cancer. The medicament adopts the Chinese medicaments capable of nourishing yin and supplementing kidney, supplying vital energy, nourishing and activating blood, tonifying qi and controlling blood, softening hardness to dissipate stagnation, removing toxicity and tonifying middle-Jiao and coordinating drug actions of a prescription, administration is increased or reduced according to the course development and classification of the leukemia to achieve the best treatment effect. 38 leukemia cases are treated non-selectively in clinical application, and the total effective rate is over 90 percent.
Description
Technical field
The present invention relates to a kind of new drug of treating leukemia, belong to technical field of Chinese medicines.
Background technology
Leukemia medically is referred to as leukemia, is the incurable disease that threatens people's life.At present, the Therapeutic Method that medically adopts is blood transfusion, radiotherapy, chemotherapy or bone marrow transplantation etc.The toxic and side effects of these Therapeutic Method is big, and the treatment phase is long, expense high (bone marrow transplantation is minimum more than 400,000 yuans, and is difficult for joining type), and general patient is difficult to afford, and effect is also undesirable; Chinese medicine treatment leukemia is with a long history; All on the books in medical science works such as Compendium of Material Medica, " book on Chinese herbal medicine is looked for the truth ", " surgeon is complete works of "; Think the generation of cancer be human body oncogene and antioncogene unbalance due to, unbalance basic reason is immune problem, regulates immune system; In conjunction with containing anticancer composition in the Chinese medicine, can fundamentally treat cancer; Therefore extensive patients hope to have very much that a kind of expense is low, instant effect, the eutherapeutic Chinese medicine of controlling leukemia, in order to alleviate the misery on the patient body, reduce the treatment cost, promote social progress.
Summary of the invention
For overcoming the above-mentioned defective of existing treatment leukemia medicine, the purpose of this invention is to provide the new drug of treating leukemia.
The inventor just follows old Chinese medicine master worker to work as the apprentice from the seventies; Begin the beginning of the nineties to work as the apprentice with the old docter of TCM; On the Chinese medicine post, adhere to clinical practice always,, sum up a kind of new drug of treating leukemia finally through practice and research for many years; Its technical characterstic is: the present invention adopts Chinese herbal medicine Ramulus et folium taxi cuspidatae (bark), Galium spurium L., Radix Ginseng, xanthorrhiza, Radix Isatidis, TIEBIANDAN, Caulis Polygoni Multiflori, Rhizoma Chuanxiong, Fructus Corni, Carapax Trionycis, Ganoderma, Herba Hedyotidis Diffusae, Rhizoma Dioscoreae Bulbiferae, the Radix Astragali, Herba Solani Lyrati, the Cortex Eucommiae, Caulis Polygoni Multiflori, Fructus Corni, Rhizomadioscoreae, Herba Scutellariae Barbatae 20 flavor Chinese herbal medicine; Be mixed with tablet or capsule is taken with traditional conventional method,, cure to hold and reach more than 90% through tens case clinical practices; Cost is low, and is effective.
Medicine according to the invention is made up of the herbal raw material of following weight parts: Ramulus et folium taxi cuspidatae (bark) 3-5 part, Galium spurium L. 4-6 part, xanthorrhiza 2-4 part, Radix Isatidis 1-2 part, Caulis Polygoni Multiflori 0.5-1, Yunnan TIEBIANDAN 1-2 part; Fructus Corni 1-3 part, Rhizoma Chuanxiong 1-2 part, Carapax Trionycis 0.5-1, Ganoderma 1-2 part, Herba Hedyotidis Diffusae 1-2 part, Rhizoma Dioscoreae Bulbiferae 0.5-1 part; Herba Solani Lyrati 1-2 part, Cortex Eucommiae 1-1.5 part, Radix Polygoni Multiflori 0.5-1 part, Rhizomadioscoreae 1-1.5 part, Radix Rehmanniae 0.5-1 part, Radix Rehmanniae Preparata 0.5-1 part; Fructus Corni 0.5-1 part, Herba Taraxaci 0.5-1 part, Poria cum Radix Pini 0.5-1 part, structure Qi 0.5-1 part, Radix Salviae Miltiorrhizae 0.5-1 part, Herba Violae 0.5-1 part; Herba Scutellariae Barbatae 0.5-1 part, Fructus Ligustri Lucidi 0.5-1 part, field dobber 0.5-1 part, triangular 0.5-1 part, Rhizoma Curcumae 0.5-1 part; Radix Angelicae Sinensis 0.1-0.5 part, Flos Carthami 0.5-1 part, Rhizoma Polygonati 0.1-0.5 part, Radix Dipsaci 0.1-0.5 part, Radix Ginseng Rubra 0.01-0.05 part; Radix Ginseng 0.1-0.5 part, Fructus Schisandrae Chinensis 0.1-0.5 part, Radix Glycyrrhizae 0.1-0.5 part, Indigo Naturalis 0.1-0.5 part, Realgar 0.01-0.05 part is totally 39 flavor medicines.
The present invention adopts Radix Salviae Miltiorrhizae, triangular, Rhizoma Curcumae, Rhizoma Chuanxiong, Flos Carthami, is used for blood circulation promoting and blood stasis dispelling; Adopt Ramulus et folium taxi cuspidatae, Ganoderma, Indigo Naturalis, Realgar, Herba Scutellariae Barbatae, Rhizoma Dioscoreae Bulbiferae, Herba Violae, Herba Solani Lyrati, Herba Taraxaci, Herba Hedyotidis Diffusae, triangular, Rhizoma Curcumae, be used for heat-clearing and toxic substances removing and have anticancer effect; The employing Carapax Trionycis is a hard masses softening and resolving; Adopting Fructus Lycii, the Radix Rehmanniae, Radix Rehmanniae Preparata, Fructus Ligustri Lucidi, Fructus Schisandrae Chinensis is enriching yin and nourishing kidney; Adopt Radix Ginseng Rubra, Radix Ginseng in order to invigorating primordial QI; Be classified as nourshing blood and promoting blood circulation with working as; Use Radix Glycyrrhizae, Rhizoma Polygonati to be nourishing qi to stop; Use Radix Glycyrrhizae to be detoxifcation invigorating middle warmer, coordinating the actions of various ingredients in a prescription.
The scope of application of medicine of the present invention: leukemia: acute lymphoblastic leukemia (ALL), acute nonlymphocytic leukemia (ANLL); Acute myeloid leukaemia (AML), chronic lymphocytic leukemia (CLL); Chronic myelogenous leukemia (CML); Chronic myelocytic leukemia; Polycythemia vera.Medicine of the present invention in addition is to hepatocarcinoma; Esophageal carcinoma; Pulmonary carcinoma also has certain curative effect.The method for using of medicine of the present invention: 1. because acute leukemia is a former malignant hematologic disease of one group of hemopoietic tissue; Leukaemia's paraplasm is arranged in bone marrow and other hemopoietic tissue widely and soak into other histoorgans; Cause the normal hematopoiesis MSOF, show as the normal hematopoiesis cell and significantly reduce; Chronic myelogenous leukemia (CML) is a kind of clone's property disease that is caused by pluripotent stem cell sudden change, comprises grain system with ripe granulocyte and antecedent thereof, and monokaryon system, red system and megakaryocytic series and some bone-marrow-derived lymphocytes are hypertrophy and accumulate and be characteristic; Develop clinical minute three phases according to the course of disease: chronic phase, accelerated period, CML-BC.2. be a kind of with mature lymphocyte propagation in blood, bone marrow, lymph node, liver, spleen and other organ pipe with to accumulate be the height variability disease of characteristic because of chronic lymphocytic leukemia (CLL).Therefore according to the different different drug treatments of distinguishing of the state of an illness with leukemic classification.3 times on the one, each 15 grams are taken after meal half an hour.Two months one courses of treatment, can cure general 3～5 courses of treatment, and cure rate can reach more than 90%.
The method for preparing of treatment leukemia new drug according to the invention: earlier with Ramulus et folium taxi cuspidatae (bark), Galium spurium L., Radix Ginseng, xanthorrhiza; Radix Isatidis; Caulis Polygoni Multiflori, Yunnan TIEBIANDAN, Fructus Corni; Rhizoma Chuanxiong; Carapax Trionycis, Ganoderma, Herba Hedyotidis Diffusae, Rhizoma Dioscoreae Bulbiferae, Herba Solani Lyrati, the Cortex Eucommiae, Radix Polygoni Multiflori, Rhizomadioscoreae, the Radix Rehmanniae, Radix Rehmanniae Preparata, Fructus Corni, Herba Taraxaci, Poria cum Radix Pini, structure Qi, Radix Salviae Miltiorrhizae, Herba Violae, Herba Scutellariae Barbatae, Fructus Ligustri Lucidi, field dobber, triangular, Rhizoma Curcumae, Radix Angelicae Sinensis, Flos Carthami, Rhizoma Polygonati, Radix Dipsaci, Radix Ginseng Rubra, Fructus Schisandrae Chinensis, Radix Glycyrrhizae, Indigo Naturalis and Realgar totally 39 flavor Chinese medicines are assorted according to quantity, dry, pulverization respectively, and mixing is mixed thoroughly; Steam three through three again and shine, be pressed into tablet or record into capsule with conventional method then.
Compare with existing treatment leukemia medicine; The present invention has following substantive distinguishing features and marked improvement: 1. this medicine has adopted Ramulus et folium taxi cuspidatae (bark) as principal agent; Because contain the No.1 cancer therapy drug in the world " paclitaxel " in the Ramulus et folium taxi cuspidatae (bark), its mechanism of action is exactly that paclitaxel can combine with trace albumin, and promotes its polymerization; The mitosis of anticancer effectively stops the propagation of cancerous cell.Also have Galium spurium L., Radix Ginseng, xanthorrhiza, Radix Isatidis in the medicine; Caulis Polygoni Multiflori, Yunnan TIEBIANDAN, Fructus Corni, Rhizoma Chuanxiong; Carapax Trionycis, thereby the advolution of control cancer cell, the anti-cancer ability of enhances human body, the while can also be improved the circulation and the metabolic function of human body; Make to be accumulated in the intravital virus of people, be scavenged into externally, reach the effect of prophylaxis of cancer through diuresis, defecation.2. this medicine adopts the Chinese medicine of relevant enriching yin and nourishing kidney, additional vigour, nourshing blood and promoting blood circulation, nourishing qi to stop, hard masses softening and resolving and detoxifcation invigorating middle warmer, coordinating the actions of various ingredients in a prescription, adds and subtracts administration according to leukemic course of disease development respectively with classification, reaches best therapeutic effect; To the high leukemia of leukocyte and be transferred to all kinds of TCAs of skeleton also effect is obvious.3. evident in efficacy: select various leukemia 38 examples of treatment according to clinical nothing, total effective rate is more than 90%, and is best with the anxious curative effect of drenching, and secondly is very red and slow grain, and early the anxious single current system of children's grain is imitated and taken second place.
The specific embodiment
Below in conjunction with clinical observation material and embodiment beneficial effect of the present invention is further specified.
Embodiment 1: clinical observation treatment:
One, physical data: cure the treatment leukaemic altogether and treat various leukemia 38 examples, wherein male 22 examples, women 16 examples: anxious grain 5 examples, anxious single 4 examples are suddenly drenched 10 examples, very red 6 examples; Slow grain 3 examples are drenched 3 examples slowly, early young grain 2 examples, preleukemia 5 examples.Total effective rate is more than 90%, and is best with the anxious curative effect of drenching, and secondly is very red and slow grain, and early the anxious single current system of children's grain is imitated and taken second place;
Two, diagnostic criteria: leukemia is the pathological changes of bone marrow, therefore need carry out bone marrow aspiration inspection and bone marrow cut sections for microscopic examination, can confirm diagnosis.In order further to confirm leukemic kind, also need extra special examined, could accurately leukemia be classified and give optimal treatment.These special examineds comprise: cellular biochemical specific stain, flow cytometer inspection, chromosome examination.General standard mostly with: 1. hemogram: the numeration of leukocyte height be neutral band form nucleus and metamyelocyte in the blood sheet more than 100 * 109/L mostly, and all the other are leaflet nuclear, middle children's grain, early young and minority myeloblast.Acidophilia and basophilic granulocyte also increase.Early stage hemoglobin and erythrocyte slightly reduce, and platelet is normal or increase, late period erythrocyte and thrombocytopenia.Aspect hemogram, must differentiate mutually with leukemoid reaction; 2. bone marrow smear: it is obviously active to extremely that bone marrow is hypertrophy, and cell divide is with blood is similar on every side, in the bone marrow sheet; Can see each phase granulocyte, wherein with in, evening children grain is main, myeloblast children's grain early more normally increases; But generally be no more than 5%～10%, have a liking for acid with (or) basophilia, erythron reduces relatively; Grain: red about 10～50:1, normoblast and megalokaryocyte often increase in early days, and reduce late period.The sophisticated neutrophil alkaline phosphatase of 90% patient is active obviously to be reduced; 3. chromosome examination: the Ph chromosome is shown in slow granulosis people more than 90%.The Ph chromosome is considered to the tumprigenicity sign of slow grain pluripotent stem cell, and the slow granulosis people Ph of minority chromosome is negative, according to have or not the Ph chromosome can slow grain for Ph positive with Ph negative two big classes, the former prevents to be superior to the latter.Other cancer diagnosis standard is pressed the hospital diagnosis conclusion;
Three, Therapeutic Method: according to patient's leukemic classification of institute and time length, the difference drug treatment, 3 times on the one, each 10～15 grams are taken after meal half an hour; Two months is a course of treatment, and can cure general 3～5 courses of treatment, and cure rate can reach more than 90%;
Four, criterion of therapeutical effect:
The acute leukemia criterion of therapeutical effect:
1. alleviation standard:
(1) alleviate (CR) fully: 1. bone marrow smear: myeloblast I type+II type (the single or former pouring+children's pouring of former list+children) is less than or equal to 5%, and erythrocyte and megalokaryocyte are normal; 2. hemogram: male's hemoglobin is more than or equal to 100g/L, and women and child's hemoglobin are more than or equal to 90g/L, and the neutrophilic granulocyte absolute value is more than or equal to 1.5 109/L, and platelet is more than or equal to 100 109/L, and peripheral blood divides apoplexy due to endogenous wind not have the leukaemia; 3. clinical: the sings and symptoms due to no leukemia is soaked into, life is normal or approaching normal;
(2) part is alleviated (PR): be less than or equal to 20% again greater than 5%; Or there is one not reach above-mentioned standard person in 2 of clinical, the hemogram;
(3) alleviate (NR): bone marrow smear, hemogram and clinical 3 all do not reach above-mentioned standard person.
2. recurrence standard: have following thrin person to be called recurrence:
(1) bone marrow myeloblast (former single, the children is single, former pouring+children drenches) is greater than 5% and less than 20%, through anti-doctor | and learn education network and collect and put leukemia treating in order and do not reach bone marrow alleviation person fully a course of treatment yet; (2) the former grain of bone marrow (former single, young single, former pouring) is greater than 20%; (3) the outer leukemiacell infiltration person of bone marrow;
3. continued complete remission: from alleviating fully, do not have leukemia relapse therebetween and reach 3～5 years persons;
4. long-term surviving: leukemia is from make a definite diagnosis, and the time-to-live reaches person more than 5 years or 5 years;
5. clinical cure: refer to stop chemotherapy 5 years or DFS and reach 10 years persons;
6. chronic myelocytic leukemia criterion of therapeutical effect:
1. alleviate fully: numeration of leukocyte < 10 109/>L; Classification is normal, no immature granulocyte (original, early, middle and late myelocyte).Platelet count normally is no more than 450 109/L;
2. part is alleviated: it is preceding more than 50% that numeration of leukocyte is reduced to treatment, at least < 20*109/>L; The blood leukocytes counting is normal, but still has juvenile cell and splenomegaly.
3. invalid: clinical and experimental check does not reach binomial standard or deterioration;
4. the acellular hereditism's reaction of cytogenetic response A., the Ph1 chromosome continues in all divisions mutually, to exist.B. small cytogenetic response: the Ph1 chromosome is suppressed to accounting for 35%～95% of division phase.C. part cytogenetic response: the Ph1 chromosome is suppressed to 5%～34% of division phase.D. complete cytogenetic response: Ph1 chromosome vanished cell.
Five, therapeutic outcome:
Treat various leukemia 38 examples, add and subtract 2～5 courses of treatment with medicine of the present invention, wherein male 22 examples, women 16 examples: anxious grain 5 examples, anxious single 4 examples are suddenly drenched 10 examples, very red 6 examples; Slow grain 3 examples are drenched 3 examples slowly, early young grain 2 examples, preleukemia 5 examples.Total effective rate is more than 90%, and is best with the anxious curative effect of drenching, and secondly is very red and slow grain, and early the anxious single current system of children's grain is imitated and taken second place.
Embodiment 2: the tablet of the new drug of treatment leukemia according to the invention:
The preparation of medicine: take by weighing each crude drug by weight ratio: 3 parts of Ramulus et folium taxi cuspidatae (bark), 4 parts of Galium spurium L.s, 1 part of Radix Ginseng, 2 parts of xanthorrhizas, 1 part of Radix Isatidis, 0.5 part of Caulis Polygoni Multiflori, 1 part of Yunnan TIEBIANDAN, 1 part of Fructus Corni, 1 part of Rhizoma Chuanxiong, 0.5 part of Carapax Trionycis; 1 part of Ganoderma, 1 part of Herba Hedyotidis Diffusae, 0.5 part of Rhizoma Dioscoreae Bulbiferae, 1 part of Herba Solani Lyrati, 1 part of the Cortex Eucommiae, 0.5 part of Radix Polygoni Multiflori; 1 part of Rhizomadioscoreae, 0.5 part in the Radix Rehmanniae, 0.5 part in Radix Rehmanniae Preparata, 0.5 part of Fructus Corni, 0.5 part of Herba Taraxaci, 0.5 part of Poria cum Radix Pini; 0.5 part of structure Qi, 0.5 part of Radix Salviae Miltiorrhizae, 0.5 part of Herba Violae, 0.5 part of Herba Scutellariae Barbatae, 0.5 part of Fructus Ligustri Lucidi, 0.5 part of field dobber; Triangular 0.5 part, 0.5 part of Rhizoma Curcumae, 0.1 part of Radix Angelicae Sinensis, 0.1 part on Flos Carthami, 0.1 part of Rhizoma Polygonati, 0.1 part of Radix Dipsaci; 0.01 part of Radix Ginseng Rubra, 0.1 part of Fructus Schisandrae Chinensis, 0.1 part in Radix Glycyrrhizae, 0.1 part of Indigo Naturalis, 0.01 part of Realgar; Totally 39 flavor Chinese medicines are assorted according to quantity, are dried, the difference pulverization, and mixing is mixed thoroughly, steams three through three again and shines, then by the conventional method compressed tablets; Every 1 gram.Embodiment 3: the capsule of the new drug of treatment leukemia according to the invention:
The preparation of medicine: take by weighing each crude drug by weight ratio: 5 parts of Ramulus et folium taxi cuspidatae (bark), 6 parts of Galium spurium L.s, 2 parts of Radix Ginseng, 4 parts of xanthorrhizas, 2 parts of Radix Isatidiss, 1 part of Caulis Polygoni Multiflori, 2 parts of Yunnan TIEBIANDANs, 3 parts of Fructus Cornis, 2 parts of Rhizoma Chuanxiongs, 1 part of Carapax Trionycis; 2 parts of Ganodermas, 1 part of Herba Hedyotidis Diffusae, 1 part of Rhizoma Dioscoreae Bulbiferae, 2 parts of Herba Solani Lyratis, 5 parts of the Cortexs Eucommiae, 1 part of Radix Polygoni Multiflori, 1.5 parts of Rhizomadioscoreae, 1 part in the Radix Rehmanniae; 1 part in Radix Rehmanniae Preparata, 1 part of Fructus Corni, 1 part of Herba Taraxaci, 1 part of Poria cum Radix Pini, 1 part of structure Qi, 0.5 part of Radix Salviae Miltiorrhizae, 0.5 part of Herba Violae; 1 part of Herba Scutellariae Barbatae, 1 part of Fructus Ligustri Lucidi, 1 part of field dobber, triangular 1 part, 1 part of Rhizoma Curcumae, 0.5 part of Radix Angelicae Sinensis, 1 part on Flos Carthami; 0.5 part of Rhizoma Polygonati, 0.5 part of Radix Dipsaci, 0.05 part of Radix Ginseng Rubra, 0.5 part of Fructus Schisandrae Chinensis, 0.5 part in Radix Glycyrrhizae, 0.5 part of Indigo Naturalis, 0.05 part of Realgar.Totally 39 flavor Chinese medicines are assorted according to quantity, are dried, the difference pulverization, and mixing is mixed thoroughly, steams three through three again and shines, and irritates into capsule by conventional method then; Every capsules 2 grams.
Model case 1:
Poplar, male, 23 years old, people from Wuhan, Hubei; The patient is no obvious inducement heating before 10 days, 38.2 ℃ of body temperature, companion's systemic pain, slight cough; Cough the sticking expectorant of a little white, gingival hemorrhage when finding to brush teeth simultaneously once " had unusual " in local blood count, obeyed Coritab certainly and failed to respond to any medical treatment and examine; Feed after being ill is few, and it is poor to sleep, and two is just normal, and body weight does not have significant change; Previously body is strong, no tuberculosis medical history, medicine-less allergy history; No tobacco and wine hobby, no similar medical history in the family; Patient's symptom is anemia, hemorrhage, heating and infection etc.; Be diagnosed as acute leukemia through certain hospital expert.Give the chemotherapy regimen treatment; Once used multiple Drug therapys such as Busulfan, cyclophosphamide; The state of an illness has stable slightly, then both leaves hospital.After see a doctor upon somebody's introduction: symptom and sign: dizzy, fatigue and weakness, 38 ℃ of low grade fever, frequent epistaxis, gingival hemorrhage; Blood pressure 24/13kpa, pulsation 96 times/minute, flushing, the binode film is congested, 2-3cm under the hepatosplenomegaly rib; Extremity are dispersed in hemorrhage ecchymosis, dimly red tongue, and yellow fur is thick and dried, and wiry and frequent pulse, card are to accumulate in the pyretic toxicity; Stagnant heat resistance network is given one and half courses of treatment of this new drug plus-minus treatment, all diseases completely without, follow up a case by regular visits to and do not have recurrence.
Model case: 2.
Hu, man, 34 years old, people from Land of Peach Blossoms, Hunan.Patient played idol and has said dizziness before one month, thought it is due to the nutrition difference at that time, and due to illness the people vomitted at that time, and every meal feed is merely one bowl of one bowl of rice water or rice flour paste, does not eat meat, dish basically; Suffer from acute non-lymphoid leukemia (M2a type) after hospital finds, be in hospital.Do not make chemotherapy, plasma transfusion 2 times, give birth to arteries and veins and ATP five times.Clothes " cleislanthin-B ".Do not feel any better.Seek medical advice upon somebody's introduction.Readme early stage, face did not have color because of the fever Pei Fusha star of once infusing in a large number, and eye is little to have the blood streak, and color is white now, gingival hemorrhage, and dizziness, myasthenia of limbs has purpura.Take 42 doses of this new drugs, remission, former side's plus-minus continues to take test rating recovery two courses of treatment normally.
Model case: 3.
Lee, woman, 19 years old, people from Land of Peach Blossoms, Hunan.Be hospitalized for treatment through the hospital diagnosis leukemia.Hair comes off when seeing a doctor, and whole body many places black speck is that the toxic and side effects that chemotherapy occurs causes.Taking this new drug heals after the course of treatment more than three entirely.Do manual work in the other places now.
Model case: 4.
The Wang, man, 60 years old, Haikou City people.Through the hospital expert diagnosing liver cancer chemotherapy of being admitted to hospital, see a doctor upon somebody's introduction.Disease is seen: hypochondriac pain, gather, jaundice, tympanites, yellow skin is black not to have the pool.According to theory of Chinese medical science " interior warp " cloud: " in healthy energy deposited, heresy can not be done, and the institute of heresy gathers, and its gas must be empty " with spleen invigorating regulate the flow of vital energy, invigorating QI and blood, nourishing the liver and kidney Chinese medicine be main.Be aided with methods such as depressed liver-energy dispersing and QI regulating, blood circulation promoting and blood stasis dispelling, heat-clearing and toxic substances removing, eliminating damp-heat, hard masses softening and resolving, eliminating mass removing mass, nourishing the liver and kidney, suppressing the hyperactive liver to relieve the wind syndrome with this new drug plus-minus, heal entirely after three courses of treatment.
[0018] model case: 5.
Chen, man, 4 years old half, people from Changsha.Be diagnosed as myelodysplastic syndrome through hospital expert, belong to leukemia symptom in early stage.Now Shanghai hospital does bone marrow and moves and grow secondary, comes diagnosis and treatment upon somebody's introduction, takes this new drug plus-minus, two the course of treatment symptom alleviate fully, in anti-.
Claims (3)
1. a new drug of treating leukemia is processed by conventional Chinese medicine method for making, and it is characterized in that: this medicine is processed by the herbal raw material of following weight parts: Ramulus et folium taxi cuspidatae (bark) 3-5 part, Galium spurium L. 4-6 part, xanthorrhiza 2-4 part, Radix Isatidis 1-2 part; Caulis Polygoni Multiflori 0.5-1, Yunnan TIEBIANDAN 1-2 part, Fructus Corni 1-3 part, Rhizoma Chuanxiong 1-2 part, Carapax Trionycis 0.5-1, Ganoderma 1-2 part; Herba Hedyotidis Diffusae 1-2 part, Rhizoma Dioscoreae Bulbiferae 0.5-1 part, Herba Solani Lyrati 1-2 part, Cortex Eucommiae 1-1.5 part, Radix Polygoni Multiflori 0.5-1 part; Rhizomadioscoreae 1-1.5 part, Radix Rehmanniae 0.5-1 part, Radix Rehmanniae Preparata 0.5-1 part, Fructus Corni 0.5-1 part, Herba Taraxaci 0.5-1 part; Poria cum Radix Pini 0.5-1 part, structure Qi 0.5-1 part, Radix Salviae Miltiorrhizae 0.5-1 part, Herba Violae 0.5-1 part, Herba Scutellariae Barbatae 0.5-1 part; Fructus Ligustri Lucidi 0.5-1 part, field dobber 0.5-1 part, triangular 0.5-1 part, Rhizoma Curcumae 0.5-1 part, Radix Angelicae Sinensis 0.1-0.5 part; Flos Carthami 0.5-1 part, Rhizoma Polygonati 0.1-0.5 part, Radix Dipsaci 0.1-0.5 part, Radix Ginseng Rubra 0.01-0.05 part, Radix Ginseng 0.1-0.5 part; Fructus Schisandrae Chinensis 0.1-0.5 part, Radix Glycyrrhizae 0.1-0.5 part, Indigo Naturalis 0.1-0.5 part, Realgar 0.01-0.05 part, totally 39 flavor medicines.
2. the new drug of treatment leukemia according to claim 1 is characterized in that: it is processed by the herbal raw material of following weight parts: 3 parts of Ramulus et folium taxi cuspidatae (bark), 4 parts of Galium spurium L.s; 1 part of Radix Ginseng, 2 parts of xanthorrhizas, 1 part of Radix Isatidis; 0.5 part of Caulis Polygoni Multiflori, 1 part of Yunnan TIEBIANDAN, 1 part of Fructus Corni; 1 part of Rhizoma Chuanxiong, 0.5 part of Carapax Trionycis; 1 part of Ganoderma, 1 part of Herba Hedyotidis Diffusae, 0.5 part of Rhizoma Dioscoreae Bulbiferae, 1 part of Herba Solani Lyrati, 1 part of the Cortex Eucommiae, 0.5 part of Radix Polygoni Multiflori; 1 part of Rhizomadioscoreae, 0.5 part in the Radix Rehmanniae, 0.5 part in Radix Rehmanniae Preparata, 0.5 part of Fructus Corni, 0.5 part of Herba Taraxaci, 0.5 part of Poria cum Radix Pini; 0.5 part of structure Qi, 0.5 part of Radix Salviae Miltiorrhizae, 0.5 part of Herba Violae, 0.5 part of Herba Scutellariae Barbatae, 0.5 part of Fructus Ligustri Lucidi, 0.5 part of field dobber; Triangular 0.5 part, 0.5 part of Rhizoma Curcumae, 0.1 part of Radix Angelicae Sinensis, 0.1 part on Flos Carthami, 0.1 part of Rhizoma Polygonati, 0.1 part of Radix Dipsaci; 0.01 part of Radix Ginseng Rubra, 0.1 part of Fructus Schisandrae Chinensis, 0.1 part in Radix Glycyrrhizae, 0.1 part of Indigo Naturalis, 0.01 part of Realgar, totally 39 flavor Chinese medicines.
3. the new drug of treatment leukemia according to claim 1 is characterized in that: it is processed by the herbal raw material of following weight parts: 5 parts of Ramulus et folium taxi cuspidatae (bark), 6 parts of Galium spurium L.s; 2 parts of Radix Ginseng, 4 parts of xanthorrhizas, 2 parts of Radix Isatidiss; 1 part of Caulis Polygoni Multiflori, 2 parts of Yunnan TIEBIANDANs, 3 parts of Fructus Cornis; 2 parts of Rhizoma Chuanxiongs, 1 part of Carapax Trionycis; 2 parts of Ganodermas, 1 part of Herba Hedyotidis Diffusae, 1 part of Rhizoma Dioscoreae Bulbiferae, 2 parts of Herba Solani Lyratis, 5 parts of the Cortexs Eucommiae, 1 part of Radix Polygoni Multiflori; 1.5 parts of Rhizomadioscoreae, 1 part in the Radix Rehmanniae, 1 part in Radix Rehmanniae Preparata, 1 part of Fructus Corni, 1 part of Herba Taraxaci, 1 part of Poria cum Radix Pini; 1 part of structure Qi, 0.5 part of Radix Salviae Miltiorrhizae, 0.5 part of Herba Violae, 1 part of Herba Scutellariae Barbatae, 1 part of Fructus Ligustri Lucidi, 1 part of field dobber; Triangular 1 part, 1 part of Rhizoma Curcumae, 0.5 part of Radix Angelicae Sinensis, 1 part on Flos Carthami, 0.5 part of Rhizoma Polygonati, 0.5 part of Radix Dipsaci; 0.05 part of Radix Ginseng Rubra, 0.5 part of Fructus Schisandrae Chinensis, 0.5 part in Radix Glycyrrhizae, 0.5 part of Indigo Naturalis, 0.05 part of Realgar, totally 39 flavor Chinese medicines.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210094444.7A CN102631518B (en) | 2012-04-01 | 2012-04-01 | New medicament for treating leukemia |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210094444.7A CN102631518B (en) | 2012-04-01 | 2012-04-01 | New medicament for treating leukemia |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102631518A true CN102631518A (en) | 2012-08-15 |
| CN102631518B CN102631518B (en) | 2014-03-12 |
Family
ID=46616198
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201210094444.7A Expired - Fee Related CN102631518B (en) | 2012-04-01 | 2012-04-01 | New medicament for treating leukemia |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102631518B (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103845696A (en) * | 2014-03-28 | 2014-06-11 | 汤震环 | Traditional Chinese medicine composition for treating leukemia as well as preparation method and application thereof |
| CN103877509A (en) * | 2014-03-29 | 2014-06-25 | 罗心刚 | Novel medicine for treating leukemia and preparation method thereof |
| CN104056194A (en) * | 2014-06-25 | 2014-09-24 | 卢文华 | Medicine for treating polycythemia vera and preparation method thereof |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102284010A (en) * | 2011-07-28 | 2011-12-21 | 北京中科血康血液病医学研究院 | Composition for treating leukemia, myeloma multiplex and myelodysplastic syndrome |
-
2012
- 2012-04-01 CN CN201210094444.7A patent/CN102631518B/en not_active Expired - Fee Related
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102284010A (en) * | 2011-07-28 | 2011-12-21 | 北京中科血康血液病医学研究院 | Composition for treating leukemia, myeloma multiplex and myelodysplastic syndrome |
Non-Patent Citations (2)
| Title |
|---|
| 王玉芝,蒲斌: "中药诱导肿瘤细胞凋亡研究进展", 《中国中西医结合外科杂志》 * |
| 秦路平,辛海量: "中药及天然药物抗白血病研究现状", 《药学实践杂志》 * |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103845696A (en) * | 2014-03-28 | 2014-06-11 | 汤震环 | Traditional Chinese medicine composition for treating leukemia as well as preparation method and application thereof |
| CN103877509A (en) * | 2014-03-29 | 2014-06-25 | 罗心刚 | Novel medicine for treating leukemia and preparation method thereof |
| CN103877509B (en) * | 2014-03-29 | 2016-06-08 | 罗心刚 | A kind of medicine and its preparation method treating leukemia |
| CN104056194A (en) * | 2014-06-25 | 2014-09-24 | 卢文华 | Medicine for treating polycythemia vera and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102631518B (en) | 2014-03-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN100998769B (en) | Chinese medicine decoction for anti-cancer and strengthening the body resistance | |
| CN101879291A (en) | Depression relieving and tranquilizing mixed decoction (powder) and pills | |
| CN108524814A (en) | A kind of Chinese medicine composition and preparation method thereof for reducing blood glucose | |
| CN102058805A (en) | Oral medicine for preventing and treating leukocytopenia caused by chemotherapy | |
| CN102579803B (en) | Medicine for treating post-chemotherapy leucopenia and preparation method thereof | |
| CN102631518B (en) | New medicament for treating leukemia | |
| CN100544755C (en) | Medicament for treatment of leukemia | |
| CN109939191A (en) | Chinese medicine composition, preparation method and the application of bone marrow suppression after a kind of antagonism chemotherapy of tumors | |
| CN100387292C (en) | Chinese medicine preparation for treating leukemia | |
| CN103877509B (en) | A kind of medicine and its preparation method treating leukemia | |
| CN104940516B (en) | A kind of Chinese medicine composition for treating chronic aplastic anemia and preparation method and application | |
| CN104524479B (en) | A kind of Chinese medicine composition for treating premenstrual syndrome and preparation method thereof | |
| CN102784315A (en) | Chinese patent medicine for treating chronic myeloid leukemia | |
| CN100388942C (en) | Leukemia treating Chinese medicine composition and its prepn | |
| CN105434864A (en) | Traditional Chinese medicine composition for treating malignant tumor | |
| CN101708300A (en) | Medicinal composition for treating scrofula, hyperplasia of mammary glands and benign lymphadenoma | |
| CN104435545A (en) | Traditional Chinese medicine preparation for treating leucopenia caused by benzene poisoning | |
| CN100493542C (en) | Traditional Chinese medicine for treating hemopathy | |
| CN101199667A (en) | Chinese medicine for treating leukemia, aplastic anemia | |
| CN101953994B (en) | Chinese medicament for treating luekopenia after concurrent chemoradiotherapy | |
| CN108324852A (en) | A kind of Chinese medicine composition for treating diabetes | |
| CN103495108A (en) | Medicine for treating chronic hypotension and preparation method for medicine | |
| CN102366619A (en) | Medicine for treating abnormal menstruation caused by asthenia of qi and blood and insomnia | |
| CN102824506A (en) | Traditional Chinese medicine preparation for treating aplastic anemia | |
| CN103142862B (en) | Oral liquid capable of regulating immune function and delaying senescence, and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| ASS | Succession or assignment of patent right |
Owner name: HUNAN RONGGUI INNOVATION TRADITIONAL CHINESE MEDIC Free format text: FORMER OWNER: HUNAN INNOVATION CHINESE MEDICINE RESEARCH CO., LTD. Effective date: 20140110 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 415700 CHANGDE, HUNAN PROVINCE TO: 411000 CHANGSHA, HUNAN PROVINCE |
|
| TA01 | Transfer of patent application right |
Effective date of registration: 20140110 Address after: 411000, No. 3, No. 401, Twentieth middle school, silver basin ridge community, Changsha, Hunan, Yuelu District Applicant after: HUNAN INNOVATION CHINESE MEDICINE RESEARCH CO., LTD. Address before: 415700, No. 578 Zhang Jiang north road, Zhangzhou Town, Taoyuan County, Changde, Hunan Applicant before: Hunan Innovation Chinese Medicine Research Co., Ltd. |
|
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20140312 Termination date: 20210401 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |